|
|
||||||||




*
Department of Microbiology and Immunology, Morehouse School of Medicine, Atlanta, GA 30310;
Department of Microbiology, The Immunobiology Vaccine Center, University of Alabama at Birmingham, Birmingham, AL 35294; and
Laboratory of Immunology, Gerontology Research Center, National Institute on Aging, Baltimore, MD 21224
RANTES is produced by lymphoid and epithelial cells of the mucosa
in response to various external stimuli and is chemotactic for
lymphocytes. The role of RANTES in adaptive mucosal immunity has not
been studied. To better elucidate the role of this chemokine, we have
characterized the effects of RANTES on mucosal and systemic immune
responses to nasally coadministered OVA. RANTES enhanced Ag-specific
serum Ab responses, inducing predominately anti-OVA IgG2a and IgG3
followed by IgG1 and IgG2b subclass Ab responses. RANTES also increased
Ag-specific Ab titers in mucosal secretions and these Ab responses were
associated with increased numbers of Ab-forming cells, derived from
mucosal and systemic compartments. Splenic and mucosally derived
CD4+ T cells of RANTES-treated mice displayed higher
Ag-specific proliferative responses and IFN-
, IL-2, IL-5, and IL-6
production than control groups receiving OVA alone. In vitro, RANTES
up-regulated the expression of CD28, CD40 ligand, and IL-12R by
Ag-activated primary T cells from DO11.10 (OVA-specific TCR-transgenic)
mice and by resting T cells in a dose-dependent fashion. These studies
suggest that RANTES can enhance mucosal and systemic humoral Ab
responses through help provided by Th1- and select Th2-type cytokines
as well as through the induction of costimulatory molecule and cytokine
receptor expression on T lymphocytes. These effects could serve as a
link between the initial innate signals of the host and the adaptive
immune system.
This article has been cited by other articles:
![]() |
U. P. Singh, S. Singh, R. Singh, R. K. Karls, F. D. Quinn, M. E. Potter, and J. W. Lillard Jr. Influence of Mycobacterium avium subsp. paratuberculosis on Colitis Development and Specific Immune Responses during Disease Infect. Immun., August 1, 2007; 75(8): 3722 - 3728. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Miao, B. A. Premack, Z. Wei, Y. Wang, C. Gerard, H. Showell, M. Howard, T. J. Schall, and R. Berahovich Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL23 J. Immunol., June 1, 2007; 178(11): 7395 - 7404. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Koya, K. Takeda, T. Kodama, N. Miyahara, S. Matsubara, A. Balhorn, A. Joetham, A. Dakhama, and E. W. Gelfand RANTES (CCL5) Regulates Airway Responsiveness after Repeated Allergen Challenge Am. J. Respir. Cell Mol. Biol., August 1, 2006; 35(2): 147 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Meddows-Taylor, S. L. Donninger, M. Paximadis, D. B. Schramm, F. S. Anthony, G. E. Gray, L. Kuhn, and C. T. Tiemessen Reduced ability of newborns to produce CCL3 is associated with increased susceptibility to perinatal human immunodeficiency virus 1 transmission J. Gen. Virol., July 1, 2006; 87(7): 2055 - 2065. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Palaniappan, S. Singh, U. P. Singh, R. Singh, E. W. Ades, D. E. Briles, S. K. Hollingshead, W. Royal III, J. S. Sampson, J. K. Stiles, et al. CCL5 Modulates Pneumococcal Immunity and Carriage J. Immunol., February 15, 2006; 176(4): 2346 - 2356. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kobayashi, T. Kohda, K. Kataoka, H. Ihara, S. Kozaki, D. W. Pascual, H. F. Staats, H. Kiyono, J. R. McGhee, and K. Fujihashi A Novel Neurotoxoid Vaccine Prevents Mucosal Botulism J. Immunol., February 15, 2005; 174(4): 2190 - 2195. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. P. Singh, S. Singh, P. N. Boyaka, J. R. McGhee, and J. W. Lillard Jr Granulocyte chemotactic protein-2 mediates adaptive immunity in part through IL-8R{beta} interactions J. Leukoc. Biol., December 1, 2004; 76(6): 1240 - 1247. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. P. Singh, S. Singh, P. Ravichandran, D. D. Taub, and J. W. Lillard Jr. Viral Macrophage-Inflammatory Protein-II: A Viral Chemokine That Differentially Affects Adaptive Mucosal Immunity Compared with Its Mammalian Counterparts J. Immunol., November 1, 2004; 173(9): 5509 - 5516. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Inouye, H. Izu, E. Takaki, H. Suzuki, M. Shirai, Y. Yokota, H. Ichikawa, M. Fujimoto, and A. Nakai Impaired IgG Production in Mice Deficient for Heat Shock Transcription Factor 1 J. Biol. Chem., September 10, 2004; 279(37): 38701 - 38709. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. DePaolo, R. Lathan, and W. J. Karpus CCR5 Regulates High Dose Oral Tolerance by Modulating CC Chemokine Ligand 2 Levels in the GALT J. Immunol., July 1, 2004; 173(1): 314 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kataoka, J. R. McGhee, R. Kobayashi, K. Fujihashi, S. Shizukuishi, and K. Fujihashi Nasal Flt3 Ligand cDNA Elicits CD11c+CD8+ Dendritic Cells for Enhanced Mucosal Immunity J. Immunol., March 15, 2004; 172(6): 3612 - 3619. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Raghavan, J. Nystrom, M. Fredriksson, J. Holmgren, and A. M. Harandi Orally Administered CpG Oligodeoxynucleotide Induces Production of CXC and CC Chemokines in the Gastric Mucosa and Suppresses Bacterial Colonization in a Mouse Model of Helicobacter pylori Infection Infect. Immun., December 1, 2003; 71(12): 7014 - 7022. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. P. Singh, S. Singh, D. D. Taub, and J. W. Lillard Jr. Inhibition of IFN-{gamma}-Inducible Protein-10 Abrogates Colitis in IL-10-/- Mice J. Immunol., August 1, 2003; 171(3): 1401 - 1406. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Bahr, X. De La Tribonniere, E. Darcissac, F. Ajana, L. Bocket, D. Sissoko, Y. Yazdanpanah, J. Dewulf, C. Amiel, and Y. Mouton Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment J. Antimicrob. Chemother., June 1, 2003; 51(6): 1377 - 1388. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. N. Boyaka, A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee Effective Mucosal Immunity to Anthrax: Neutralizing Antibodies and Th Cell Responses Following Nasal Immunization with Protective Antigen J. Immunol., June 1, 2003; 170(11): 5636 - 5643. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-M. Kang and R. W. Compans Enhancement of Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus J. Virol., March 15, 2003; 77(6): 3615 - 3623. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Lillard Jr, U. P. Singh, P. N. Boyaka, S. Singh, D. D. Taub, and J. R. McGhee MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity Blood, February 1, 2003; 101(3): 807 - 814. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Estell, G. Braunstein, T. Tucker, K. Varga, J. F. Collawn, and L. M. Schwiebert Plasma Membrane CFTR Regulates RANTES Expression via Its C-Terminal PDZ-Interacting Motif Mol. Cell. Biol., January 15, 2003; 23(2): 594 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Harandi, K. Eriksson, and J. Holmgren A Protective Role of Locally Administered Immunostimulatory CpG Oligodeoxynucleotide in a Mouse Model of Genital Herpes Infection J. Virol., December 20, 2002; 77(2): 953 - 962. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |